To investigate the relative efficacy of terbutaline Turbuhaler® and Salbutamol pressurized Metered Dose Inhaler (pMDI) a single blind study
Study identifier:D589LC00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A study to investigate the relative efficacy of terbutaline Turbuhaler® 0.4 mg and Salbutamol pressurized Metered Dose Inhaler (pMDI) 200 μg - a single blind, single dose, randomized, crossover, phase III study in Japanese adult asthma patients
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Terbutaline Turbuhaler®, Salbutamol pMDI
Sex
All
Actual Enrollment
24
Study type
Interventional
Age
16 Years +
Date
Study Start Date: 01 Mar 2010
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler® | Drug: Terbutaline Turbuhaler® 0.4 mg, inhalation, single dose Other Name: Bricanyl Turbuhaler Other: pMDI placebo pMDI Placebo pMDI 2 inhalations Other: Placebo Turbuhaler® Placebo Turbuhaler 1 inhalation |
| Experimental: 2 salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI | Drug: Salbutamol pMDI 200 μg, inhalation, single dose Other Name: Saltanol Other: pMDI placebo pMDI Placebo pMDI 2 inhalations Other: Placebo Turbuhaler® Placebo Turbuhaler 1 inhalation |
Contacts
Investigators
Principal Investigator
Tomas Andersson
AstraZeneca
